The Lancet. Gastroenterology and hepatology

Visão geral
Metrics
Identidade
Ver todos

Qualis

A1

código do país

GB

tipo

journal

publicação venue de

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. 1:1-10. 2023-01-01
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. 1:1-622. 2023-01-01
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. 00:00197. 2023-01-01
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. 1:1. 2023-01-01
Launch of the International Living Donor Liver Transplantation Outcomes Registry. S2468:1. 2023-01-01
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 7:307-317. 2022-01-01
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. 1:1-1. 2022-01-01
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. 7:128-140. 2022-01-01
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. 7:28-37. 2022-01-01
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. 7:17-27. 2022-01-01
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. 2:1-415. 2022-01-01
Global multi-stakeholder endorsement of the MAFLD definition. 01:388-390. 2022-01-01
Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 1:1-647. 2022-01-01
Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. X:Y. 2022-01-01
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. 1:1. 2022-01-01
May isoflavones prevent breast cancer risk?. 68:1487-1488. 2022-01-01
New insights on the surgical management of ulcerative colitis in the 21st century. 1:1-1. 2022-01-01
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas.. 22:S2468-1253. 2022-01-01
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. 7:171-185. 2022-01-01
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. 7:1092-1102. 2022-01-01
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. 6:185-198. 2021-01-01
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. 6:826-849. 2021-01-01
Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply. 6:691-692. 2021-01-01
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. 1:1. 2021-01-01
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. 21:S2468. 2021-01-01
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. 6:30340-x-72. 2021-01-01
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. 1:1. 2021-01-01
ALEH position statement on the redefinition of fatty liver disease. 02:01-8. 2020-01-01
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. 1:1. 2020-01-01
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 5:245-266. 2020-01-01

tem uma área de assunto

publisher

Elsevier BV

is open access

False invalid format

is in DOAJ

False invalid format